tbuckley/cabot-search huggingface dataset:
Advanced Techniques and Awaited Clinical Applications for Human Pluripotent Stem Cell Differentiation into Hepatocytes
Authors: Eléanor Luce, Antonietta Messina, Jean‐Charles Duclos‐Vallée, Anne Dubart‐Kupperschmitt
Journal: Hepatology (2021)

Liver transplantation is currently the only curative treatment for several liver diseases such as acute liver failure, end-stage liver disorders, primary liver cancers, and certain genetic conditions. Unfortunately, despite improvements to transplantation techniques, including live donor transplantation, the number of organs available remains insufficient to meet patient needs. Hepatocyte transplantation has enabled some encouraging results as an alternative to organ transplantation, but primary hepatocytes are little available and cannot be amplified using traditional two-dimensional culture systems. Indeed, although recent studies have tended to show that three-dimensional culture enables long-term hepatocyte culture, it is still agreed that, like most adult primary cell types, hepatocytes remain refractory to in vitro expansion. Because of their exceptional properties, human pluripotent stem cells (hPSCs) can be amplified indefinitely and differentiated into any cell type, including liver cells. While many teams have worked on hepatocyte differentiation, there has been a consensus that cells obtained after hPSC differentiation have more fetal than adult hepatocyte characteristics. New technologies have been used to improve the differentiation process in recent years. This review discusses the technical improvements made to hepatocyte differentiation protocols and the clinical approaches developed to date and anticipated in the near future.
PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma
Authors: Shaofang Wu, Xiaolong Li, Feng Gao, John F de Groot, Dimpy Koul, W K Alfred Yung
Journal: Neuro-Oncology (2021)

Temozolomide (TMZ) resistance in glioblastoma multiforme (GBM) is mediated by the DNA repair protein O6-methylguanine DNA methyltransferase (MGMT). MGMT promoter methylation (occurs in about 40% of patients) is associated with loss of MGMT expression (MGMT-) that compromises DNA repair, leading to a favorable response to TMZ therapy. The 60% of patients with unmethylated MGMT (MGMT+) GBM experience resistance to TMZ; in these patients, understanding the mechanism of MGMT-mediated repair and modulating MGMT activity may lead to enhanced TMZ activity. Here, we report a novel mode of regulation of MGMT protein activity by poly(ADP-ribose) polymerase (PARP).MGMT-PARP interaction was detected by co-immunoprecipitation. PARylation of MGMT and PARP was detected by co-immunoprecipitation with anti-PAR antibody. O6-methylguanine (O6-MetG) adducts were quantified by immunofluorescence assay. In vivo studies were conducted in mice to determine the effectiveness of PARP inhibition in sensitizing GBM to TMZ.We demonstrated that PARP physically binds with MGMT and PARylates MGMT in response to TMZ treatment. In addition, PARylation of MGMT by PARP is required for MGMT binding to chromatin to enhance the removal of O6-MetG adducts from DNA after TMZ treatment. PARP inhibitors reduced PARP-MGMT binding and MGMT PARylation, silencing MGMT activity to repair O6-MetG. PARP inhibition restored TMZ sensitivity in vivo in MGMT-expressing GBM.This study demonstrated that PARylation of MGMT by PARP is critical for repairing TMZ-induced O6-MetG, and inhibition of PARylation by PARP inhibitor reduces MGMT function rendering sensitization to TMZ, providing a rationale for combining PARP inhibitors to sensitize TMZ in MGMT-unmethylated GBM.
Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC
Authors: Jessica M. Konen, B. Leticia Rodriguez, Aparna Padhye, Joshua K. Ochieng, Laura Gibson, Lixia Diao, Natalie W. Fowlkes, Jared J. Fradette, David H. Peng, Robert J. Cardnell, Jeffrey J. Kovacs, Jing Wang, Lauren A. Byers, Don L. Gibbons
Journal: Cancer Research (2021)

The epithelial-to-mesenchymal transition (EMT) is a dynamic epigenetic reprogramming event that occurs in a subset of tumor cells and is an initiating step toward invasion and distant metastasis. The process is reversible and gives plasticity to cancer cells to survive under variable conditions, with the acquisition of cancer stem cell-like characteristics and features such as drug resistance. Therefore, understanding survival dependencies of cells along the phenotypic spectrum of EMT will provide better strategies to target the spatial and temporal heterogeneity of tumors and prevent their ability to bypass single-inhibitor treatment strategies. To address this, we integrated the data from a selective drug screen in epithelial and mesenchymal KRAS/p53 (KP)-mutant lung tumor cells with separate datasets including reverse-phase protein array and an
Apprenticeship model would better prepare medical students for practice, says RCP
Authors: Nikki Nabavi
Journal: BMJ (2021)

The final year of medical school should be taught under an apprenticeship model to better prepare students for practice, the Royal College of Physicians (RCP) has said.

On 7 January the college launched a blueprint for expanding medical school places.1 It follows a call made by the college in 2018 for UK medical school places to be doubled, from 7500 to 15 000.2

The college said, among other recommendations set out in the blueprint, that governments and regulators should consult with medical schools “about moving towards …
Patterns and Trends of Cancer Screening in Canada: Results From a Contemporary National Survey
Authors: Omar Abdel-Rahman
Journal: Journal of the National Comprehensive Cancer Network (2021)

The aim of this study was to assess the patterns and trends of colorectal, breast, and cervical cancer screening within a contemporary cohort of Canadian adults.Canadian Community Health Survey datasets (2007-2016) were accessed and 3 cohorts were defined: (1) a colorectal cancer (CRC) screening cohort, defined as men and women aged 50 to 74 years with complete information about CRC screening tests and their timing; (2) a breast cancer screening cohort, defined as women aged 40 to 74 years with complete information about mammography and its timing; and (3) a cervical cancer screening cohort, defined as women aged 25 to 69 years with complete information about the Papanicolaou (Pap) test and its timing. Multivariable logistic regression analysis was then performed to evaluate factors associated with not having timely screening tests at the time of survey completion.A total of 99,820 participants were considered eligible for the CRC screening cohort, 59,724 for the breast cancer screening cohort, and 46,767 for the cervical cancer screening cohort. Among eligible participants, 43% did not have timely recommended screening tests for CRC, 35% did not have timely mammography (this number decreased to 26% when limiting the eligible group to ages 50-74 years), and 25% did not have a timely Pap test. Lower income was associated with not having a timely recommended screening tests for all 3 cohorts (odds ratios [95% CI]: 1.86 [1.76-1.97], 1.89 [1.76-2.04], and 1.96 [1.79-2.14], respectively). Likewise, persons self-identifying as a visible minority were less likely to have timely recommended screening tests in all 3 cohorts (odds ratios for White race vs visible minority [95% CI]: 0.87 [0.83-0.92], 0.85 [0.80-0.91], and 0.66 [0.61-0.70], respectively).More than one-third of eligible individuals are missing timely screening tests for CRC. Moreover, at least one-quarter of eligible women are missing their recommended breast and cervical cancer screening tests. More efforts from federal and provincial health authorities are needed to deal with socioeconomic disparities in access to cancer screening.
Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Authors: Ellen K. Chang, Dayana Chanson, Jennifer Berano Teh, Aleksi Iukuridze, Kelly Peng, Stephen J. Forman, Ryotaro Nakamura, F. Lennie Wong, LiYing Cai, Saro H. Armenian
Journal: Journal of Clinical Oncology (2021)

To examine the incidence and risk factors for de novo atrial fibrillation (AF) after allogeneic hematopoietic cell transplantation (HCT) and to describe the impact of AF on HCT-related outcomes.A retrospective cohort study design was used to examine AF and associated outcomes in 487 patients who underwent allogeneic HCT from 2014 to 2016 and to characterize patient- and HCT-related risk factors. A nested case-control study design was used to describe the association between pre-HCT echocardiographic measures and future AF events.The median age at HCT was 52.4 years (18.1-78.6); the median time to AF was 117.5 days (4.0-1,405.0). The 5-year cumulative incidence of AF was 10.6%. Older (≥ 50 years) age (hazard ratio [HR], 2.76; 95% CI, 1.37 to 5.58), HLA-unrelated donor (HR, 2.20; 95% CI, 1.18 to 4.12), dyslipidemia (HR, 2.40; 95% CI, 1.23 to 4.68), and pre-HCT prolonged QTc interval (HR, 2.55; 95% CI, 1.38 to 4.72) were independent risk factors for AF. Despite having comparable left ventricular systolic function, patients who developed AF were significantly more likely to have lower left atrial ejection fraction, left atrial reservoir function, and elevated tricuspid regurgitant jet velocity prior to HCT, compared with patients who did not. The incidence rate of stroke after AF was 143 per 1,000 person-years. In adjusted analyses, AF was associated with a 12.8-fold (HR, 12.76; 95% CI, 8.76 to 18.57) risk of all-cause mortality and 15.8-fold (HR, 15.78; 95% CI, 8.70 to 28.62) risk of nonrelapse mortality.The burden of AF after allogeneic HCT population is substantial, and the development of AF is associated with poor survival. We identified important associations between patient demographics, pre-HCT cardiac parameters, HCT-related exposures, and risk of AF, setting the stage for targeted prevention strategies during and after HCT.
The impact of size on particle drainage dynamics and antibody response
Authors: Simon Zinkhan, Anete Ogrina, Ina Balke, Gunta Reseviča, Andris Zeltins, Simone de Brot, Cyrill Lipp, Xinyue Chang, Lisha Zha, Monique Vogel, Martin F. Bachmann, Mona O. Mohsen
Journal: Journal of Controlled Release (2021)

Vaccine-induced immune response can be greatly enhanced by mimicking pathogen properties. The size and the repetitive geometric shape of virus-like particles (VLPs) influence their immunogenicity by facilitating drainage to secondary lymphoid organs and enhancing interaction with and activation of B cells and innate humoral immune components. VLPs derived from the plant Bromovirus genus, specifically cowpea chlorotic mottle virus (CCMV), are T = 3 icosahedral particles. (T) is the triangulation number that refers to the number and arrangements of the subunits (pentamers and hexamers) of the VLPs. CCMV-VLPs can be easily expressed in an E. coli host system and package ssRNA during the expression process. Recently, we have engineered CCMV-VLPs by incorporating the universal tetanus toxin (TT) epitope at the N-terminus. The modified CCMVTT-VLPs successfully form icosahedral particles T = 3, with a diameter of ~30 nm analogous to the parental VLPs. Interestingly, incorporating TT epitope at the C-terminus of CCMVTT-VLPs results in the formation of Rod-shaped VLPs, ~1 μm in length and ~ 30 nm in width. In this study, we have investigated the draining kinetics and immunogenicity of both engineered forms (termed as Round-shaped CCMVTT-VLPs and Rod-shaped CCMVTT-VLPs) as potential B cell immunogens using different in vitro and in vivo assays. Our results reveal that Round-shaped CCMVTT-VLPs are more efficient in draining to secondary lymphoid organs to charge professional antigen-presenting cells as well as B cells. Furthermore, compared to Rod-shaped CCMVTT-VLPs, Round-shaped CCMVTT-VLPs led to more than 100-fold increased systemic IgG and IgA responses accompanied by prominent formation of splenic germinal centers. Round-shaped CCMVTT-VLPs could also polarize the induced T cell response toward Th1. To our knowledge, this is the first study investigating and comparing the draining kinetics and immunogenicity of one and the same VLP monomer forming nano-sized icosahedra or rods in the micrometer size.
Conflicts of interest among the UK government’s covid-19 advisers: what has the configuration of SAGE got to do with it?
Authors: Allan House
Journal: BMJ (2021)

Thacker's point about failure to declare conflicts of interest, and especially financial conflicts, is surely correct 1 -but what has the configuration of expertise on the Scientific Advisory Group for Emergencies (SAGE) got to do with that argument?The author implies that modellers are over-represented within the group, illustrating (by innuendo) the malign effects of SAGE's relationship to government by implying that it is not up to the job.These kinds of remarks represent an undesirable drift towards the use of rhetorical devices, rather than logical argument, to support a position-creating an atmosphere of scepticism about the competence of scientific endeavour as well as about its integrity.
Enhanced Expression of CXCR4 Facilitates the Trafficking of Anti-c-Kit Chimeric Antigen Receptor (CAR) T Cells to Bone Marrow and Achieves Effective Donor Stem Cell Engraftment
Authors: Yasuyuki Arai, Cristina I. Corsino, Sherry M. Koontz, Masaki Tajima, Mary A. Black, Colin L. Sweeney, Uimook Choi, Steven A. Feldman, Mary C. Dinauer, Harry L Malech
Journal: Blood (2017)
Loneliness, worries, anxiety, and precautionary behaviours in response to the COVID-19 pandemic: A longitudinal analysis of 200,000 Western and Northern Europeans
Authors: Tibor V. Varga, Feifei Bu, Agnete S. Dissing, Leonie K. Elsenburg, Joel J. Herranz Bustamante, Joane Matta, Sander K.R. van Zon, Sandra Brouwer, Ute Bültmann, Daisy Fancourt, Klaus Hoeyer, Marcel Goldberg, Maria Melchior, Katrine Strandberg-Larsen, Marie Zins, Amy Clotworthy, Naja H. Rod
Journal: The Lancet Regional Health - Europe (2021)
Immune MAL2-practice: breast cancer immunoevasion via MHC class I degradation
Authors: Devin Dersh, Jonathan W. Yewdell
Journal: Journal of Clinical Investigation (2021)

The success of tumor immunotherapy, while partial, confirms the existence and importance of tumor immunosurveillance. CD8+ T cell recognition of tumor-specific peptides bound to MHC class I (MHC-I) molecules is central to this process. In this issue of the JCI, Fang, Wang, et al. describe a unique tumor immunoevasion strategy based on endocytosis and degradation of MHC-I complexes mediated by the trafficking factor MAL2. Notably, MAL2 expression was associated with poor prognosis of breast cancer, and its downregulation enhanced CD8+ T cell recognition of breast cancer in various experimental models. This work demonstrates that a deeper understanding of tumor interference with MHC-I stability and trafficking has considerable potential for enhancing immunotherapies.
Breastfeeding promotes early neonatal regulatory T‐cell expansion and immune tolerance of non‐inherited maternal antigens
Authors: Hannah Wood, Animesh Acharjee, Hayden Pearce, Mohammed Nabil Quraishi, Richard Powell, Amanda Rossiter, Andrew Beggs, Andrew Ewer, Paul Moss, Gergely Toldi
Journal: Allergy (2021)

Breastfeeding is associated with long-term health benefits, such as a lower incidence of childhood infections, asthma, obesity and autoimmune disorders. However, little is known regarding how the maternal and neonatal immune systems interact after parturition when the neonate receives nutrition from maternal breast milk.
Sitagliptin to Prevent Acute Graft-versus-Host Disease
Authors: Paul J. Martin
Journal: New England Journal of Medicine (2021)

Pharmacologic methods to prevent acute graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HSCT) have long relied on combinations of immunosuppressive medications and antibodies to inhibit or deplete donor T cells that recognize alloantigens in the recipient. In this issue of the Journal, Farag et al. report that a regimen of sitagliptin added to a standard immunosuppressive regimen of tacrolimus and sirolimus resulted in an impressively low incidence of acute GVHD after HSCT with filgrastim-mobilized blood cells from HLA-matched related or unrelated donors.1 Sitagliptin inhibits the dipeptidyl peptidase 4 (DPP-4) activity of CD26, a highly multifunctional cell-surface glycoprotein expressed in . . .
연구논문 : 만성 B형간염 환자에 대한 초치료제로서 엔테카비어의 항바이러스 효과와 그 예측인자
Authors: 명형준, 정숙향, 김진욱, 김희섭, 장제혁, Lee Dong Ho, Kim， Nayoung, Hwang， Jin-Hyeok, Park Young Soo, Sang Hyub， Lee
Journal: Clinical and Molecular Hepatology (2010)

목적: 항바이러스 약제에 대한 치료 경험이 없는 국내 만성 B형간염 환자의 초치료제로서 엔테카비어의 치료 효과와 치료 반응의 예측인자를 알아보고자 하였다. 대상 및 방법: 2007년 2월부터 2009년8월까지 본원에 내원한 만성 B형간염 환자 중 과거 항바이러스 약제 사용력이 없으며 24주 이상 엔테카비어를 복용한 160명을 대상으로 후향적으로 연구하였다. 엔테카비어 투여 중 혈청 HBV DNA의 소실(2000 copies/mL 미만)을 바이러스 반응으로, 혈청 ALT의 정상화를 생화학적 반응으로 정의하였고, 혈청 HBeAg 소실과 HBeAg 혈청전환을 평가하였다. 바이러스 돌파는 HBV DNA치가 2번의 연속된 검사에서 이전 검사 결과보다 1 log10이상 증가하였을 경우로 정의하였다. 결과: 총 160명의 환자 중, 남자는 85명(53.1%), HBeAg 양성인환자는 85명(53.1%), 간경변이 동반된 환자는 70명(43.8%)이었고, 치료 전 혈청 ALT의 중앙값은 99IU/L, 혈청 HBV DNA의 중앙값은 7.57 log10copies/mL였다. 평균 58.8주 동안 추적관찰하였다. 누적 바이러스 반응률은 12주에 37.5%, 24주에 68.1%, 48주에 87.4%, 72주에 95.8%였고, 누적 생화학적 반응률은 12주에 40.0%, 24주에 66.2%, 48주에 84.5%, 72주에 92.7%였다. 누적 HBeAg 소실률은 12주에 10.6%, 24주에 18.8%, 48주에 27.0%, 2주에 34.5%였고, 누적 HBeAg 혈청전환율은 12주에 3.5%, 24주에 7.1%, 48주에 9.0%, 72주에 13.2%였다. 일차 치료 실패에 해당하는 환자나 바이러스 돌파 현상을 보인 환자는 없었다. 바이러스 반응과 관련된 유의한 예측인자는 치료 전 HBeAg이 음성, HBV DNA치의 상용로그 변환값이 8 미만인 경우였다. 결론: 엔테카비어 치료는 국내의 항바이러스제 치료 경험이 없는 만성 B형간염 환자에서 강력한 항바이러스 효과를 보였으며, 바이러스 반응의 예측인자는 치료 시작 전 HBeAg의 유무, HBV DNA 값이다. 향후 장기간의 치료 성적에 대한 연구가 필요하다.
The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy
Authors: Minsu Kwon, Hanul Jung, Gi-Hoon Nam, In-San Kim
Journal: Journal of Controlled Release (2021)

Cancer immunotherapy (CI) represented by immune checkpoint inhibitors (ICIs) presents a new paradigm for cancer treatment. However, the types of cancer that attain a therapeutic benefit from ICIs are limited, and the efficacy of these treatments does not meet expectations. To date, research on ICIs has mainly focused on identifying biomarkers and patient characteristics that can enhance the therapeutic effect on tumors. However, studies on combinational strategies for CI are being actively conducted to overcome the resistance to ICI treatment. Moreover, it has been confirmed that dramatic anticancer effects are achieved through "neoadjuvant" immunotherapy with ICIs in treatment-naïve cancer patients; consequently, it has become necessary to consider how to best apply cancer immunotherapies for patients, even with respect to their tumor stages. In this review, we sought to discuss the right timing of ICI treatment in consideration of the progression of cancer with a changing tumor-immune microenvironment. Furthermore, we investigated which types of combinational treatments and their corresponding sequences of administration could optimize the therapeutic effect of ICIs to expand the applicable target of ICIs and increase their therapeutic efficacy. Finally, we discussed several delivery pathways and methods that can maximize the effect of ICIs.
Pharmacogenetics of advanced lung cancer: Predictive value of functional genetic polymorphism AGXT Pro11Leu in clinical outcome?
Authors: Maria Joana Catarata, Margarida Lourenço, Maria Fátima Martins, João Frade, Alice Pêgo, Carlos Robalo Cordeiro, Rui Medeiros, Ricardo Ribeiro
Journal: Pulmonology (2021)

AGXT gene codes for the enzyme alanine glyoxylate aminotransferase, which is involved in hepatic peroxisomal metabolism of platinum-based chemotherapeutic agents. The association of genetic variant AGXT rs34116584 on the clinical outcome and response to chemotherapy of patients with non-small cell lung cancer (NSCLC) remains to be established. Our aim was to evaluate the association of functional AGXT gene polymorphism in NSCLC progression, considering as primary and secondary endpoint, progression free survival (PFS) and overall survival (OS), respectively. Genotyping of theAGXT rs34116584 genetic polymorphism was performed by mass spectrometry on 168 DNA samples from patients with NSCLC (stages IIIA-IVB). Univariate survival analysis included the study of Kaplan-Meier curves with the Log-Rank test, while Cox regression was used as a multivariate analysis. Multivariate analysis showed shorter PFS for T carriers [HR = 2.0, 95% CI, 1.4−3.0, p < 0.0001] and shorter OS [HR = 1.8, 95% CI, 1.1−3.0, p = 0.017] globally, as well as in a subgroup of patients (n = 144) treated with first line platinum-based chemotherapy [HR = 2.0, 95% CI, 1.3–3.1, p = 0.001] and [HR = 1.8, 95% CI, 1.1–3.1, p = 0.026], respectively. This polymorphism seems to have an impact on NSCLC progression, opening new perspectives for its inclusion as a pharmacogenetic predictor of response to platinum-based chemotherapy.
Oncogenic N-Ras Mitigates Oxidative Stress–Induced Apoptosis of Hematopoietic Stem Cells
Authors: Gina M. Ney, Kevin B. Yang, Victor Ng, Lu Liu, Meiling Zhao, Wun Kuk, Lila Alaka, Leilani Sampang, Adam Ross, Morgan A. Jones, Xi Jin, Laura M. McKay, Hadie Evarts, Qing Li
Journal: Cancer Research (2021)

Leukemic relapse is believed to be driven by transformed hematopoietic stem cells (HSC) that harbor oncogenic mutations or have lost tumor suppressor function. Recent comprehensive sequencing studies have shown that mutations predicted to activate Ras signaling are highly prevalent in hematologic malignancies and, notably, in refractory and relapsed cases. To better understand what drives this clinical phenomenon, we expressed oncogenic
Abstract 775: p66Shc Deletion Rescues EPC Differentiation Deficit Induced By High Glucose
Authors: Fabio Martelli, Valeria Di Stefano, Chiara Cencioni, Maurizio C Capogrossi
Journal: Circulation (2007)

Background. Reduced endothelial progenitor cell (EPC) differentiation is one relevant component of angiogenesis impairment in diabetic patients. A close relationship exists between hyperglycemia, o...
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Authors: G.N. Hortobagyi, S.M. Stemmer, H.A. Burris, Y.S. Yap, G.S. Sonke, S. Paluch-Shimon, M. Campone, K. Petrakova, K.L. Blackwell, E.P. Winer, W. Janni, S. Verma, P. Conte, C.L. Arteaga, D.A. Cameron, S. Mondal, F. Su, M. Miller, M. Elmeliegy, C. Germa, J. O’Shaughnessy
Journal: Annals of Oncology (2019)

Ann Oncol 2018; 29: 1541–1547 (doi: 10.1093/annonc/mdy155) The following has been added to the ‘Disclosure’ section: “CLA reports fees for advisory work with Novartis Pharmaceuticals (specifically participation on a Steering Committee for a clinical trial).” Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancerAnnals of OncologyVol. 29Issue 7PreviewThe phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer. Here, we report updated efficacy and safety data, together with exploratory biomarker analyses, from the MONALEESA-2 study. Full-Text PDF Open Access
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities
Authors: Luciano Garofano, Simona Migliozzi, Young Taek Oh, Fulvio D’Angelo, Ryan D. Najac, Aram Ko, Brulinda Frangaj, Francesca Pia Caruso, Kai Yu, Jinzhou Yuan, Wenting Zhao, Anna Luisa Di Stefano, Franck Bielle, Tao Jiang, Peter Sims, Mario L. Suvà, Fuchou Tang, Xiao-Dong Su, Michele Ceccarelli, Marc Sanson, Anna Lasorella, Antonio Iavarone
Journal: Nature Cancer (2021)